INTRODUCTION
Allogeneic bone marrow transplantation (allo-BMT) has emerged as an important treatment for several malignant and nonmalignant diseases. Unfortunately, the success of allo-BMT is limited by serious complications. In particular, diffuse lung injury occurs in 25-55% of allo-BMT recipients and significantly contributes to morbidity and mortality after BMT [1] [2] [3] [4] . Historically, approximately 50% of all pneumonias seen after SCT have been secondary to infection, but the judicious use of broad-spectrum antimicrobial prophylaxis in recent years has tipped the balance of pulmonary complications from infectious to non-infectious causes 5 . Non-infectious lung injury that occurs in the acute setting has been defined as idiopathic pneumonia syndrome (IPS) 4 . A retrospective study from Seattle showed a lower incidence and earlier onset of IPS than previously reported, but the typical clinical course involving the rapid onset of respiratory failure leading to death remained unchanged 6 . A recent review from the University of Michigan Medical Center demonstrated that the frequency of IPS after allogeneic SCT ranged from 5% to 25% depending upon donor source and the degree of antigenic mismatch between donor and recipient 7 . Day 100 mortality was approximately 80% and the median time from the diagnosis of IPS to death was 13 days despite aggressive treatment with high dose steroids and broadspectrum antimicrobial therapy 7 .
The pathophysiology of IPS is complex and a significant body of clinical and experimental data has supported roles for both allospecific donor T cells [8] [9] [10] and the production of inflammatory cytokines 9, [11] [12] [13] [14] [15] . With respect to the latter, both hyporesponsiveness of donor cells to lipopolysaccharide (LPS) stimulation 12 and the neutralization of tumor necrosis factor alpha only.
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Inflammatory chemokines are also produced in the lung during murine IPS 16 and is important for monocyte, macrophage and T cell recruitment in several inflammatory models [23] [24] [25] [26] . MCP-1 is produced by hematopoietic, endothelial, epithelial and smooth muscle cells in response to inflammatory stimuli such as interleukin-1β (IL-1β) and TNFα [27] [28] [29] [30] [31] .
Abrogation of CCR2/MCP-1 interactions either by neutralization or deficiency of the ligand or receptor results in the impaired recruitment of monocytes, macrophages and T cells in animal models of inflammatory and pulmonary diseases 23, 24, 26, [32] [33] [34] [35] [36] [37] .
In light of the established role of donor accessory cells and lymphocytes in the development of IPS [8] [9] [10] 12 , we examined the contribution of CCR2/MCP-1 interactions to this process after allo-BMT. We hypothesized that MCP-1 expression in the lung and CCR2 expression on donor leukocytes would have significant impact on recruitment of monocytes, macrophages and T cells to the lung during IPS. Our results support this hypothesis and demonstrate that the expression of both MCP-1 and CCR2 is significantly increased after allo-BMT. 
MATERIALS AND METHODS

Mice and bone marrow transplantation
Bronchoalveolar lavage (BAL)
Mice were sacrificed by exsanguination and BAL was performed as previously described 40 .
BAL fluid (BALF) supernatants were frozen for subsequent analysis of cytokine and chemokine content, and cells were counted before being analyzed by flowcytometry or used for cytospinanalysis.
Cytospin-analysis
Aliquots of 50,000 cells were resuspended in 250µl buffer solution, centrifuged at 1200 rpm for 3 minutes onto Cytoslides (Thermo Shandon, Pittsburgh, PA) and stained using the Diff-Quik 
RNase Protection Assay (RPA)
After perfusion of the pulmonary vascular system with ice-cold PBS, whole lung tissue was retrieved at various time points after BMT and stored at -80˚C. mRNA was extracted from whole lungs using TRIzol following the manufacturer's protocol (GibcoBRL, Grand Island, NY) and quantitated by spectrophotometry. The multiprobe-template sets mCK-5b and mCR-5 were purchased from BD PharMingen (San Diego, CA 
Anti-MCP-1 treatment
In some experiments, BMT recipients were treated with polyclonal antibodies against MCP-1 or with pre-immune serum 42 . The antiserum containing polyclonal Abs directed against mouse MCP-1/CCL2 was generated in New Zealand White rabbits using a well-established protocol 43 .
The specificity of the anti-MCP-1/CCL2 antiserum was rigorously screened before its use in an experiment, and it lacked cross-reactivity with other chemokines and cytokines 42 . Allo-BMT recipients were injected intraperitoneally with 250µl of either anti-MCP-1 antibodies (titers of 10 7 /ml) or pre-immune serum on day 10, 12, 16, 20, 24 and 28 after transplant. Syngeneic BMT recipients received pre-immune serum only or were left untreated.
BALF MCP-1 levels in BMT recipients and healthy volunteers
BALF samples analyzed for MCP-1 levels were obtained from BMT recipients with either acute (IPS) or chronic non-infectious pulmonary dysfunction and from healthy volunteers. BALF was collected in a systematic manner in all BMT recipients. A total volume of 2ml/kg of sterile saline (max volume 180cc) was instilled into the patient's lungs. Collected BALF was pooled, divided into aliquots and frozen for subsequent analysis. BALF MCP-1 protein levels were measured using a human MCP-1 ELISA kit (BD Pharmingen, San Diego, CA) according to the manufacturer's protocol. All samples were run in duplicate and the sensitivity of the assay was 15 pg/ml.
Statistical considerations
All values are expressed as the mean ± SEM. The parametric independent sample t-test was used for statistical comparisons between groups unless the number of samples was <5, in which case 
RESULTS
Donor monocytes/macrophages and T cells migrate into the lung and cause lung injury after allogeneic BMT
Lethally irradiated B6D2F1 mice were transplanted with syngeneic (B6D2F1) or allogeneic (B6 macrophages also co-expressed CD11b (Figure 3c ) consistent with a previously described phenotype of newly recruited alveolar macrophages 44, 45 .
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For 
is increased on monocytes and macrophages recruited to the alveolar space after allogeneic BMT. (c) F4/80+ macrophages in the BALF show a phenotype previously described for newly recruited monocytes to the alveolar space (F4/80+ / CD11b+) 44, 45 .
For Monocytes, macrophages and T cells are significant sources of TNFα after allo-BMT 12, 49, 50 , and
TNFα is important in the development of IPS 11,13,51,52 . Furthermore, the soluble p55 TNF receptor (sTNFRI) has been shown to correlate with GVHD and other transplant-related complications in humans 53 . We therefore measured BALF levels of TNF and sTNFRI and found only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From that both were decreased in recipients of CCR2 -/-BMT compared to CCR2 +/+ controls ( Figure   4i ). Finally, similar reductions in IPS severity were seen using CCR2 -/-donors in the context of a single MHC class I (B6 bm1) or class II (B6 bm12) mismatch between donor and host demonstrating that the reduction in lung injury was not a strain specific phenomenon (Figure 4j ). 
CCR2 deficiency of T cells and macrophages does not alter alloreactivity to host antigens or cytokine production
We hypothesized that the reduction in IPS severity after CCR2 -/-BMT was secondary to a defect in the recruitment of CCR2 -/-donor cells to the lung rather than from intrinsic defects in cytokine production and alloreactivity of CCR2 deficient monocytes/macrophages and T cells, only.
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In vivo neutralization of MCP-1 after allo-BMT reduces the severity of IPS
We next determined the effects of in vivo neutralization of MCP-1 on the development of IPS.
B6D2F1 recipient mice received either syngeneic or allogeneic BMT as described above. Allo-BMT recipients were injected intraperitoneally with 250µl of either polyclonal anti-MCP-1 antibodies or control serum starting on day 10 after transplant as described in Materials and Methods. We chose this schedule to block MCP-1 prior to peak expression of pulmonary mRNA levels and the influx of donor mononuclear cells to the lung. We also opted to avoid neutralizing MCP-1 in the setting of severe systemic inflammation that is seen during the first week after allo-BMT, since a similar strategy proved to be deleterious in an animal model of sepsis 54 .
Syngeneic controls received pre-immune serum at the same volume and schedule. To exclude a potential non-specific effect of rabbit serum, some syngeneic controls received no treatment. All groups were analyzed by day 30 for lung histopathology and BAL fluid cellularity. MCP-1 neutralization had no effect on mortality (data not shown). Consistent with previous experiments in this system, allo-BMT recipients receiving control serum developed significant lung injury, whereas immunoneutralization of MCP-1 resulted in a significantly reduced IPS severity and BALF cellularity (Figure 6a+b ). Administration of rabbit serum had no effect on lung histopathology in syngeneic controls nor were symptoms of serum sickness observed (data not shown).
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MCP-1 levels are increased in the BAL fluid of patients with IPS after allogeneic BMT
In a final set of experiments, we measured MCP-1 levels in BAL fluid obtained from BMT recipients with either acute (IPS) or chronic non-infectious pulmonary dysfunction, who were enrolled on clinical protocols approved by the University of Michigan's Institutional Review Board (IRB) and from healthy volunteers. Adult and pediatric BMT recipients (median age 20 yrs; range 1 to 43 yrs) were diagnosed with IPS if they fulfilled criteria defined by Clark et al. 4 .
IPS was diagnosed within 100 days (median 12 days; range 9 to 56) after full intensity, 5/6 (n=1) or 6/6 (n=10) HLA-matched allogeneic BMT from either a related (n=2) or an unrelated (n=9) donor, had clinical and radiographic evidence of diffuse lung injury and had no evidence of an active systemic (blood/urine) or lower respiratory tract infection as assessed by BAL at time of study entry. Patients who required inotropic blood pressure support or in whom pulmonary dysfunction was believed to be secondary to heart failure or fluid overload were not included.
Chronic pulmonary dysfunction was defined as obstructive lung disease (OLD) or restrictive lung disease (RLD) as described in methods. BAL samples were collected at study entry, processed and assayed for MCP-1 as described in Materials and Methods. As shown in figure 7 , BAL MCP-1 levels were markedly elevated in patients with IPS compared to patients with chronic pulmonary dysfunction and healthy controls.
DISCUSSION
IPS remains a frequently fatal complication after allo-BMT. Risk factors for IPS have included conditioning with total body irradiation (TBI), acute GVHD, older recipient age, initial diagnosis of malignancy other than leukemia, and the use of methotrexate (MTX) for GVHD prophylaxis 3, 6, [55] [56] [57] [58] . The likelihood of developing IPS increases with the number of identified risk factors 2 . A recent report from Seattle found that despite greater patient age and a similar incidence of acute GVHD, recipients of allogeneic SCT using non-myeloablative conditioning have a reduced risk of IPS compared to patients receiving myeloablative conditioning 59 . Once established, pulmonary toxicity was severe in each group and resulted in respiratory failure in the majority of patients. These findings suggest that the intensity of SCT conditioning plays an important role in the development of IPS, and they are consistent with data generated from two mouse SCT models showing that the lung is sensitive to the combined effects of radiation and alloreactive T cells 60,61 .
Potential etiologies for IPS include direct toxic effects of SCT conditioning regimens, occult pulmonary infections, and the release of inflammatory cytokines that have been implicated in other forms of pulmonary injury [62] [63] [64] . Immunologic factors may also be important as suggested by the association of IPS and allogeneic (vs. autologous or syngeneic) SCT and severe GVHD (vs. mild or absent GVHD) 2, 5, 6, 55, 65 . Acute GVHD often precedes IPS, suggesting a possible causal relationship between the two disorders 3, 55, 66, 67 . Although the consistent association between lung injury and GVHD after experimental SCT also supports such an etiology 8, 9, 13, 40, 52 , the role of GVHD and specifically alloreactive donor T lymphocytes in the pathogenesis of IPS remains a topic of considerable debate. Epithelial apoptosis is usually attributed to T-cellonly.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From mediated injury and is considered pathognomonic for acute GVHD. While observed in the lungs of some patients with IPS 68 , epithelial apoptosis has not been consistently identified in allogeneic SCT recipients with pulmonary dysfunction 67, 69, 70 . The heterogeneity of pulmonary histopathology after allogeneic SCT is complicated further by the non-specific changes that occur after mechanical ventilation and by the limited quality and quantity of lung biopsy tissue.
Despite the lack of classic acute GVHD histopathology, several lines of evidence suggest that the lung is susceptible to a two-pronged immunologic attack involving both inflammatory cytokines and cellular effector pathways. However, the mechanisms by which activated leukocytes traffic to the lung and cause inflammation after allogeneic SCT remain unresolved. only.
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We demonstrate that both donor T cells and accessory cells infiltrate the lung as histopathology progresses after allo-BMT; turnover of donor T lymphocytes and macrophages in the bronchoalveolar space is complete by week 2 and 4, respectively. We hypothesized that the chemokine receptor CCR2 and its principal ligand MCP-1 are critical to the recruitment of these donor cells to the lung after allo-BMT. Our data support this hypothesis and demonstrate that pulmonary MCP-1 mRNA and protein levels are increased early after transplantation and are followed by Since previous work has identified a significant role for Th1 effector lymphocytes in the development of IPS [8] [9] [10] , the reduction in lung injury seen after allogeneic CCR2 -/-BMT could only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From have also been attributed in part to alterations in T cell function, recruitment or both. Our results demonstrate that the absence of CCR2 on donor cells resulted in reduced numbers of lymphocytes in the broncho-alveolar space but had no effect on the functional capacity of these cells; lymphocytes from CCR2 -/-mice showed no deficits in proliferation, INFγ production or CTL activity to alloantigens both in vitro and in vivo. It was also possible that diminished lung injury after CCR2 -/-BMT was secondary to a Th2 shift in the pulmonary immune response after only.
